Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
triptan |
| gptkbp:approvedBy |
1997
|
| gptkbp:ATCCode |
N02CC02
|
| gptkbp:bioavailability |
74%
|
| gptkbp:brand |
Amerge
Naramig |
| gptkbp:CASNumber |
143388-64-1
|
| gptkbp:contraindication |
ischemic heart disease
uncontrolled hypertension history of stroke |
| gptkbp:discoveredBy |
gptkb:Glaxo_Wellcome
|
| gptkbp:drugClass |
antimigraine agent
|
| gptkbp:eliminationHalfLife |
6 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C17H25N3O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Naratriptan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
serotonin 5-HT1B/1D receptor agonist
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
29%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness drowsiness dry mouth |
| gptkbp:synonym |
Naratriptan hydrochloride
|
| gptkbp:usedFor |
migraine
|
| gptkbp:bfsParent |
gptkb:Triptans
|
| gptkbp:bfsLayer |
7
|